P&G wins patent lawsuit for osteoporosis therapy against Teva
Feb 28 (Reuters) - Procter & Gamble Co (PG.N: Quotazione) said it won a patent infringement lawsuit for osteoporosis therapy Actonel against Teva Pharmaceuticals USA Inc.
Procter & Gamble said the ruling of U.S. District Court of Delaware protects P&G's rights in the U.S. to exclusively market the osteoporosis therapy Actonel. The ruling upheld the P&G patent, rejecting Teva's validity challenge, it added.
The Actonel patent life extends through the end of 2013, excluding any potential extensions, P&G said in a statement. (Reporting by Dilipp S. Nag in Bangalore; Editing by Anil D'Silva)
© Thomson Reuters 2017 Tutti i diritti assegna a Reuters.